A Novel Neuromodulation Approach to Target Small Fiber Neuropathy Early in Diabetes and Measure Functional Recovery
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Change in Pain level
研究概览
简要总结
This is a prospective randomized control trial. Participants enrolled into the study will be randomized into one of three groups, two of which are treatment groups and the third is a control group. A time course of measurements before and after spinal cord stimulation (SCS) treatment (where applicable) will assess pain, DPN severity, small fiber nerve activity, and metabolic health markers.
详细描述
Peripheral neuropathy (PN) is caused by diabetes, aging, chemotherapy, and over 30 other conditions, and impacts more than 30 million patients in the US alone. Diabetes is the number one cause of peripheral neuropathy, and more than half of patients with diabetes will eventually develop diabetic peripheral neuropathy (DPN), a complex set of symptoms including pain, numbness, tingling, and burning. Spinal cord stimulation (SCS) is an approved intervention for the treatment of chronic pain, including DPN. Spinal cord stimulation has had FDA approval for the treatment of painful DPN since 2015. This study is being done to learn more about the diagnosis of DPN and treatment of DPN with SCS.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Over 18 years old
- •Diagnosis of diabetic peripheral neuropathy refractory to treatment with gabapentin or pregabalin and at least 1 other class of analgesic
- •Diagnosis of medically refractory pain secondary to diabetic neuropathy
- •Presence of pain for 12 months
- •Lower limb pain intensity score ≥4 on a visual analog scale
- •Pass pre-operative neuropsychological assessment (surgical group only)
- •Capable of providing informed consent
排除标准
- •Severe medical comorbidities that, in the opinion of the surgeon, exclude the patient from surgical intervention
- •Spinal disease with severe spinal stenosis or spinal cord compression in the region of the proposed spinal cord stimulator lead placement
- •Coagulopathy that cannot be corrected
- •Unable to discontinue blood thinning medications
- •Hemoglobin A1c level greater than 10
- •Presence of systemic infection
- •Pregnancy
研究组 & 干预措施
Conventional Medical Management (CMM). Group1
Spinal Cord Stimulator (SCS) immediate activation. Group 2
干预措施: Spinal Cord Stimulator Implantation (SCS) (Device)
Spinal Cord Stimulator (SCS) Delayed activation. Group 3
干预措施: Spinal Cord Stimulator Implantation (SCS) (Device)
结局指标
主要结局
Change in Pain level
时间窗: 18 months post baseline
change in Visual analog pain scale (VAS). The VAS endpoints range from 'no pain at all' to 'pain as bad as it could be'
Change in Diabetic Peripheral Neuropathy (DPN) Pain using the Neuropathic pain diagnostic questionnaire (DN4)
时间窗: 18 months post baseline
Neuropathic Pain Diagnostic "Douleur Neuropathique 4" questionnaire (DN4) is a screening questionnaire to help identify neuropathic pain (NP) in clinical practice and research. It is a clinican-administered questionnaire consisting of 10 items.The first 7 symptoms items are scored by interviewing the patient, and the 3 remaining items are scored by means of clinical examination. The scores are added and a score of 4 or more out of 10 is suggestive of neuropathic pain
Change in PROMIS quality of life in relation to pain level
时间窗: 18 months post baseline
Change in patient-reported outcomes measurement (PROMIS 29)
次要结局
- change in neuropathic symptoms using Michigan Neuropathy Screening instrument(18 months post baseline)
研究者
Brian Dalm
Associate Professor, Neurological Surgery
Ohio State University